中国经济网北京2月2日讯 A股市场全天震荡调整。截至今日收盘，上证综指报4015.75点，跌幅2.48%，成 交额11635.33亿元；深证成指报13824.35点，跌幅2.69%，成交额14212.32亿元；创业板指报3264.11点，跌 幅2.46%，成交额6768.91亿元。 板块方面，白酒、电网设备板块涨幅居前，贵金属、油气开采及服务、工业金属等板块跌幅居前。 | 序号 | 板块 | 涨跌幅(%)▼ | | 总成交量 (万手) = 总成交额 (亿元) ▼ | 净流入 (亿元) ▼ | 上涨家数 | 下跌家数 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 白酒 | 2.60 | 573.98 | 363.45 | 6.54 | 19 | 1 | | 2 | 电网设备 | 2.09 | 4993.40 | 750.44 | 10.93 | 91 | 43 | | 3 | 银行 | -0.26 | 5472.13 | 417.21 | 23.77 | 17 | 24 | | র্ব | 影视院线 | -0.34 | 1654.92 | 1 ...

Core Viewpoint - Shenghui Integration (603163.SH) has announced a plan to issue convertible bonds to raise up to RMB 55 million, which will be used for high-tech industry projects [1][2]. Fundraising Details - The total amount to be raised from the issuance of convertible bonds is capped at RMB 55 million, including this amount [2]. - The net proceeds after deducting issuance costs will be allocated to several specific projects, including cleanroom engineering and electromechanical projects, with a total investment of RMB 113.43 million [1]. Project Allocation - The funds will be distributed among various projects as follows: - Clean Electromechanical Engineering: Total investment of RMB 384.45 million, using RMB 11 million from the raised funds - Dust-Free Room Engineering: Total investment of RMB 220.48 million, using RMB 6 million from the raised funds - Electromechanical Package: Total investment of RMB 126.01 million, using RMB 9.5 million from the raised funds - Electromechanical Engineering: Total investment of RMB 403.39 million, using RMB 28.5 million from the raised funds [1]. Bond Issuance Details - The bonds will have a face value of RMB 100 each and will be issued at par value, with a maturity of six years from the issuance date [3]. - The interest rate will be determined based on national policies, market conditions, and company specifics, with interest paid annually [3]. - The conversion period for the bonds will start six months after issuance and last until maturity, allowing bondholders to choose whether to convert their bonds into shares [3]. Previous Fundraising - Shenghui Integration previously raised RMB 54.5 million by issuing 20 million shares at RMB 27.25 per share on October 13, 2022, with a net amount of RMB 48.53 million after costs [4].

Core Insights - The Chinese biopharmaceutical industry experienced a historic leap in 2025, with 76 innovative drugs approved for market, a 58% increase from 2024, and total licensing transactions exceeding $130 billion, marking record highs in both transaction volume and value [1] - The "China strategy" has become a central topic at the JPM 2026 conference, highlighting the importance of global collaboration in the biopharmaceutical sector [2] Industry Developments - Chinese biopharmaceutical companies face significant challenges when entering markets like the US and Europe, including stringent regulatory requirements and high competition, with a success rate of only 0.4% for Chinese biopharmaceuticals from clinical phase I to market in the US [3] - The complexity of healthcare systems in Europe and the strict approval processes by the EMA further complicate market entry for Chinese firms [3] Transaction Trends - There has been a notable decline in cross-border License-in transactions from 2022 to 2025, while License-out transactions have surged, with the total value in 2025 being approximately 2.5 times that of 2024 [4] - New transaction structures such as the NewCo model and Royalty Monetization are emerging as preferred options for Chinese pharmaceutical companies, indicating a shift towards a more integrated global partnership approach [4][5] Future Outlook - The next 3-5 years are expected to be significant for business development (BD) in China's biopharmaceutical sector, with a strong recovery in financing and an optimistic outlook for international collaboration [7][8] - The industry is positioned to leverage its comprehensive R&D capabilities and cost advantages, with innovative drugs priced at about one-tenth of their US counterparts, suggesting a continued role as a source of global innovation [8]

Core Viewpoint - Taxfriend Co., Ltd. (603171.SH) announced a share reduction plan by its controlling shareholder, Ningbo Sicheng Venture Capital Partnership, intending to sell up to 12,190,350 shares, representing a maximum of 3% of the company's total share capital, without changing the control of the company [1][2]. Group 1: Share Reduction Plan - Ningbo Sicheng plans to reduce its holdings from March 3, 2026, to June 2, 2026, through centralized bidding and block trading, with a total potential cash-out of approximately 892 million yuan based on the last closing price of 73.18 yuan per share [1]. - The total shares to be reduced include a maximum of 4,063,450 shares through centralized bidding (up to 1% of total shares) and 8,126,900 shares through block trading (up to 2% of total shares) [1]. Group 2: Current Shareholding Status - As of the announcement date, Ningbo Sicheng holds 209,914,539 shares, accounting for 51.66% of the total share capital, with these shares acquired before the IPO [1]. - Ningbo Sicheng and Zhang Zhengchao are acting in concert, with a combined holding of 302,214,539 shares, representing 74.37% of the total share capital [1]. Group 3: Previous Share Reductions - Since starting to reduce its holdings on March 14, 2025, Ningbo Sicheng has cumulatively reduced 13,181,200 shares, realizing approximately 623 million yuan [2]. - The previous reductions occurred at various average prices per share, with the highest average price being 52.73 yuan and the lowest at 43.14 yuan [3].

一、市场表现 二、重要新闻 1、据巴基斯坦媒体《黎明报》报道，1月26日，巴基斯坦国家银行(巴央行)发表声明，将本国关键政策利率维持在10.5%不变。声明同时指出，2025年12月 巴基斯坦的总体通胀率为5.6%，核心通胀率稳定在7.4%的较高水平附近，外部经常账户出现2.44亿美元的赤字，导致2026财年上半年出现12亿美元的赤字。 2、据巴基斯坦媒体《国民报》1月26日报道，2025至2026财年上半年(2025年7月至2025年12月)，美国仍为巴基斯坦最大商品出口目的地，其次为中国和英 国。巴基斯坦国家银行(巴央行)公布数据显示，统计期间，巴基斯坦对美出口总额为31.77亿美元，对华出口总额为12.16亿美元，对英出口总额为10.96亿美 2026年2月2日 元。 3、巴基斯坦财政部1月27日发布了《2025年12月月度经济更新及展望》，报告指出2025至2026财年上半年(2025年7月至2025年12月)巴基斯坦宏观经济持续 稳定，消费者物价指数为5.2%，去年同期为7.2%；大规模制造业增长6.0%；政府总收入增长了7.8%，总开支减少6.2%；经常账户在统计期间出现了12亿美 元赤字，而去年为 ...

Core Viewpoint - The announcement reveals that the shareholder, Lianyungang Yiweida Enterprise Management Partnership, plans to reduce its holdings in Lidin Optoelectronics by up to 12 million shares, which represents a strategic move by the controlling shareholders to liquidate part of their investment [1][2]. Group 1: Shareholder Reduction Plan - Lianyungang Yiweida plans to reduce its holdings by a maximum of 12,000,000 shares within three months after the announcement, with up to 8,000,000 shares through block trades and 4,000,000 shares through competitive bidding [1]. - The estimated cash-out amount from the reduction, based on the previous closing price of 40.52 yuan per share, is approximately 486,240,000 yuan [1]. - As of the announcement date, Yiweida holds 76,556,900 shares, accounting for 18.64% of the total share capital of the company [1]. Group 2: Shareholder Structure - The controlling shareholder, Xiamen Yiweida Investment Co., Ltd., along with its concerted actors, holds a total of 353,865,900 shares, representing 86.17% of the company's total share capital [2]. - The concerted action relationship is due to control by the same party, specifically the actual controller Wu Fubao [1][2]. Group 3: Previous Share Reduction Activities - In the previous year, the controlling shareholders liquidated over 200 million yuan, with specific reductions including 3,403,100 shares by Yiweida and others [3]. - The average reduction price for Yiweida ranged from 28.27 yuan to 35.19 yuan per share, totaling 100,487,609 yuan [3]. - The total cash-out amount from the previous reductions by all controlling shareholders and their concerted actions was approximately 218,782,546 yuan [3].

2026年1月28日，招商证券股份有限公司发布研报《浙矿股份："业务结构+运营模式"升级共振并购铅银 矿打造第二成长曲线》，研究员为郭倩倩、刘伟洁、高杨洋、张洵伊、朱鹏丞。研报称，看好浙矿股份 在砂石矿山和金属矿山、资源回收利用主业的发展前景，同时公司并购海外铅银矿有望在未来增厚业 绩。公司对应25/26/27年的PE分别为65.4、53.9、48.1，首次覆盖给予"增持"投资评级。 中国经济网北京2月2日讯浙矿股份（300837）(300837.SZ)今日收报45.10元，跌幅13.14%，总市值45.10 亿元。 ...

Core Viewpoint - Zhenbaodao Pharmaceutical is experiencing robust production growth across its manufacturing bases, driven by strong market demand and a well-structured supply chain that enhances its competitive edge in the industry [1][5]. Group 1: Production and Supply Chain - The company's core formulation production lines are operating at full capacity, with a fully booked production schedule for Q1 2026, particularly for cardiovascular and respiratory products [1]. - Zhenbaodao has established GAP cooperative planting bases in Heilongjiang, Gansu, and Shandong, ensuring consistent quality and cost control of key raw materials through standardized processes and a comprehensive quality traceability system [1]. - The modern logistics system facilitates the efficient transportation of raw materials to the company's processing facilities, where advanced automated production lines operate under centralized control, ensuring precision and efficiency [2]. Group 2: Technological Integration - The integration of SCADA systems allows for real-time monitoring of production processes, ensuring that any deviations from standard values trigger alerts, thus maintaining high consistency across product batches even during full-capacity operations [3]. - The use of MES systems records every batch's process data and quality inspection results, creating a complete digital archive that enhances traceability from raw materials to finished products [2][3]. Group 3: Research and Development - Zhenbaodao is investing in R&D to build a future-oriented product pipeline, focusing on deep development of existing major products and exploring new clinical values [4]. - The company is actively involved in the development of innovative traditional Chinese medicine, biopharmaceuticals, and classic formulations, with recent breakthroughs in antibody-drug conjugates (ADC) for non-Hodgkin lymphoma [4]. Group 4: Competitive Advantage - The company's deep control over key raw materials and standardized production and quality systems provide it with strong operational certainty and profitability resilience amid macroeconomic uncertainties [5]. - Zhenbaodao's comprehensive supply chain model enhances its risk resistance and cost advantages, forming a "moat" that secures market supply and quality safety, laying a foundation for sustainable growth in future industry competition [5].

菱电电控原拟通过发行股份及支付现金的方式向北京兰之穹等27名交易对方购买其合计持有的奥易 克斯98.4260%股份。本次交易预计不构成重大资产重组，不构成关联交易，不构成重组上市。 自本次交易事项筹划以来，公司严格按照相关法律法规及规范性文件要求，积极组织交易各相关方 推进本次交易相关工作。鉴于本次交易涉及相关方较多，使得交易方案事项推进时间较长，综合考虑市 场环境较交易筹划初期已发生一定变化等因素，为切实维护公司和广大投资者利益，经公司董事会审慎 研究，决定终止本次发行股份及支付现金购买资产事项，并向上海证券交易所申请撤回本次交易相关申 请文件。 中国经济网北京2月2日讯 菱电电控(688667.SH)披露公告，公司于2026年1月30日召开第四届董事会 第八次会议，审议通过了《关于终止发行股份及支付现金购买资产事项并撤回申请文件的议案》，同意 公司终止发行股份及支付现金购买资产事项并撤回申请文件。 菱电电控于2021年3月12日在上海证券交易所科创板上市，发行数量为12,900,000股，发行价格为 75.42元/股，保荐人（主承销商）为长江证券承销保荐有限公司，保荐代表人为梁彬圣、郭忠杰。该股 目前处于 ...

近日，有餐饮商家入驻美团外卖平台时，发现必须上传门店"一镜到底"视频，画面须连续、无剪辑，完 整展示门店门头、经营环境、后厨实况及资质等情况。 这是美团外卖率先推出的"一镜到底"门店真实性核验功能，目前已在金华、银川、青岛、哈尔滨、贵阳 等8个城市试点上线，主要面向新入驻商家，同时也是日常抽查的重要举措。该功能今年内将逐步推广 至全国，进一步提升门店真实性核验效果，未按照规定上传视频、视频造假将受到平台相应处置。 2025年12月4日，外卖平台推荐性国家标准《外卖平台服务管理基本要求》发布。针对"幽灵外卖"问 题，标准提出了平台内商户入驻条件，商户应提供带有门店定位的"一镜到底"视频，平台应根据视频核 验定位信息与商户证照的一致性。 证照和地址不符，就容易出现"虚假门店""无证经营"等食品安全隐患。对此，美团外卖自主研发并率先 试点"一镜到底"门店真实性核验功能，将证照地址一致纳入智能风险管控体系，推动食品安全风险的主 动发现和精准治理。 治理食品安全问题的关键并非有没有堂食，而是商家能否规范经营，愿不愿意公开透明地展示食安信 息。商户上传从门头到后厨的"一镜到底"视频，实现了经营场景的可视化、可追溯审查。 ...